Abstract
We report the clinical results of sustainedly integrating imatinib and interferon-α into maintenance therapy in the patients ineligible for allogeneic hematopoietic stem cell transplantation (allo-HSCT). Maintenance therapy lasted for 5 years with imatinib 400 mg daily, interferon-α 3 million units, 2∼3 doses per week, and chemotherapy including vindesine and dexamethasone scheduled monthly in first year, once every 2 months in second year, and once every 3 months in third year. The chemotherapy was discontinued after 3 years and the imatinib and interferon-α continued for another 2 years. For 41 patients without allo-HSCT with a median follow-up of 32 months, the 3-year DFS and OS were 42.7 ± 8.6% and 57.9 ± 8.4%, respectively. Our study suggests that sustaining maintenance with low-dose chemotherapy, imatinib and interferon-α improved survival of adult Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) patients ineligible for allo-HSCT, and even provided an opportunity for cure. BCR/ABL persistent negativity at 6 and 9 months may have benefit to choose suitable patients for the imatinib/interferon-α maintenance strategy.
References
Aug 1, 1996·Controlled Clinical Trials·M Schemper, T L Smith
Oct 3, 2002·Leukemia·G VisaniM Baccarani
Oct 24, 2002·Blood·Urban J ScheuringOliver G Ottmann
Oct 26, 2002·Leukemia·A HochhausR Hehlmann
Sep 27, 2003·Leukemia·B WassmannO G Ottmann
Oct 11, 2003·Blood·Deborah A ThomasHagop Kantarjian
Jan 14, 2004·British Journal of Haematology·Meir WetzlerClara D Bloomfield
Dec 14, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Masamitsu YanadaUNKNOWN Japan Adult Leukemia Study Group
Apr 28, 2006·Blood·Barbara WassmannOliver G Ottmann
Jul 14, 2006·Leukemia·A DelannoyX Thomas
Oct 26, 2006·Blood·Adrienne de LabartheUNKNOWN Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL)
Jan 11, 2007·Blood·Marco VignettiFranco Mandelli
Apr 5, 2007·Blood·Heike PfeiferOliver G Ottmann
Feb 15, 2008·Leukemia·P P PiccalugaG Visani
Feb 27, 2009·Blood·Adele K FieldingAnthony H Goldstone
Jun 24, 2009·British Journal of Haematology·Leonardo PotenzaMario Luppi
Oct 3, 2009·Haematologica·Josep-Maria RiberaUNKNOWN Grupo Español de Trasplante Hemopoyético Groups
Jul 8, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Renato BassanAlessandro Rambaldi
Jun 21, 2011·Blood·Bengt SimonssonUNKNOWN Nordic CML Study Group
Aug 9, 2011·Blood·Sabyasachi BhattacharyaSerge Y Fuchs
Sep 21, 2011·Blood·Robin FoàUNKNOWN GIMEMA Acute Leukemia Working Party
Jan 21, 2012·International Journal of Hematology·Hidehiro ItonagaYasushi Miyazaki
Jun 19, 2012·Leukemia·S LeeC-W Park
Oct 2, 2012·Blood·Max S ToppRalf C Bargou
Jul 10, 2013·Blood·Farhad RavandiHagop M Kantarjian
Oct 16, 2014·The New England Journal of Medicine·Shannon L MaudeStephan A Grupp
Apr 17, 2015·Blood·Yves ChalandonUNKNOWN Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL)
Oct 4, 2015·The Lancet Oncology·Elias JabbourSusan O'Brien
Citations
Dec 8, 2017·Leukemia & Lymphoma·He LiTing Liu
Jun 24, 2017·PloS One·Peter M AlexanderTimothy S Pardee
Nov 21, 2020·Scientific Reports·Sining LiuXiaodong Mo
Jun 29, 2021·PloS One·Ben PonvilawanWeerapat Owattanapanich
Aug 27, 2021·PloS One·Wanhua Zhang, Erguai Jang